Bordetella pertussis and B. parapertussis are the causative agents of whooping cough, resulting in approximately 50 mil lion cases and 300,000 deaths annually worldwide (28) . While whooping cough is considered by the CDC to be a reemerging disease (5) , the relative incidences of B. pertussis and B. para pertussis are not clear (50) . It is known, however, that the resurgence of whooping cough roughly correlates with the in troduction of acellular pertussis vaccines (5) . These vaccines contain only B. pertussis-derived antigens and confer little to no protection against B. parapertussis (9, 14, 15, 23, 27, 28) . Cur rent acellular pertussis vaccines contain some combination of filamentous hemagglutinin, pertactin, and fimbriae 2 and 3, all of which are expressed by both B. pertussis and B. parapertussis, and pertussis toxin, which is 7>. pertussis specific (33, 34) . Based on genome sequences, the levels of amino acid sequence identity between B. pertussis and B. parapertussis filamentous hemagglutinin, pertactin, and fimbria 2 and 3 proteins are about 98, 91, 71, and 92% (35) , and antibodies raised against these antigens from B. pertussis cross-react with B. paraper tussis (17, 31) . However, immunization with purified B. per tussis filamentous hemagglutinin or pertactin does not con fer protection against B. parapertussis (17) . B. pertussis fimbriae confer some protection against B. parapertussis, but at much lower levels than they protect against B. pertussis (52) . Based on these observations and the fact that B. para pertussis infection induces protective immunity to itself (56, 58) , we hypothesized that the lack of protective antigens from B. parapertussis may be part of the reason why current whooping cough vaccines are ineffective against this bacterium.
Although B. pertussis and B. parapertussis are very closely related (8, 35, 48) , they differ in the structure of their lipopoly saccharides (LPS) (1, 2, 39, 40, 47) . B. pertussis produces a lipooligosaccharide containing lipid A and a branched-chain core oligosaccharide with a complex trisaccharide modification but lacks the O antigen due to a natural deletion of the wbm locus responsible for its synthesis (39, 47) . B. parapertussis LPS is similar to B. pertussis LPS but lacks the trisaccharide modi fication and includes an O antigen (39, 40) . In addition to conferring serum resistance by inhibiting C3 deposition onto the surfaces of bacteria (11) , the O antigen enables B. parapertussis to avoid B. pertussis-induced immunity by preventing antibody bind ing to cross-reactive antigens on the surfaces of B. parapertussis cells (56, 59 ) . Since the O antigen is one dominant surface antigen recognized by B. parapertussis immune sera (56) and has been shown previously to be a protective antigen of various pathogenic bacteria (22, 36) , we hypothesized that the O antigen is a protec tive antigen of B. parapertussis.
To assess the role of the O antigen in the generation of an Animal experiments. C57BL/6 mice were obtained from Jackson Laboratories. C3_/_ mice were kind gifts from Rick Wetsel and have been described elsewhere (7) . All mice were bred in our Bordetella-ixcc, specific-pathogen-free breeding rooms at The Pennsylvania State University. Four-to six-week-old mice were sedated with 5% isoflurane (Abbott Laboratory) in oxygen and inoculated by pipetting of 50 pl of phosphate-buffered saline (PBS; Omnipur) containing 5 X 105 CFU of bacteria onto the external nares (18) . This method reliably distrib utes the bacteria throughout the respiratory tract (13) . For rechallenge experi ments, mice were treated with gentamicin in drinking water (10 (37) . After 3 days, the supernatants were collected and analyzed for gamma interferon (IFN-y) and interleukin-10 (IL-10) production via enzyme-linked immunosorbent assays (ELISAs) per the instructions of the manufacturer (R&D Systems).
Titer ELISAs. Antibody titers were determined as described previously (25, 56) . In brief, exponential-phase live CN2591 or CN2591 Lwbm bacteria were diluted to 5 X 107 CFU/ml in a 1:1 mix of 0.2 M sodium carbonate and 0.2 M sodium bicarbonate buffers. The wells of 96-well plates were coated with these antigens, and the plates were incubated for 2 h at 37°C in a humidified chamber and then washed and blocked. Serum samples from individual mice were diluted 1:50, added to the first wells of the plates, and serially diluted 1:2 across the plates, and the plates were incubated for 2 h at 37°C. Plates were washed, probed with a 1:4,000 dilution of goat anti-mouse Ig horseradish peroxidase-conjugated antibodies (Southern Biotech) for 1 h, and washed again prior to visualization with 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt in phosphate-citrate buffer with hydrogen peroxide at an absorbance of 405 nm. Titers were determined via the end point method based on optical densities in identically treated wells probed with naive sera.
Western blot analysis. Lysates containing 107 CFU of heat-killed CN2591 or CN2591 Lwbm were run on 10% sodium dodecyl sulfate-poly acrylamide gel electrophoresis gels under denaturing conditions. Polyvinylidene difluoride membranes (Millipore) were probed overnight with either naive sera or sera from CN2591-or CN2591 Awbm-inoculated mice at a 1:500 dilution. Goat anti-mouse Ig horseradish peroxidase-conjugated antibodies (Southern Biotech) were used at a dilution of 1:10,000 as the detector antibody (56, 57) . The membrane was visualized with enhanced chemiluminescence Western blotting detection reagent (Pierce Biotechnology).
Statistical analysis. The mean ± standard error was determined for all ap propriate data. Two-tailed, unpaired Student's t tests were used to determine the statistical significance of differences between groups. All experiments were per formed at least twice with similar results. (Fig. 1, right) . Interestingly, B. paraper tussis infection induced more protection against the O-antigendeficient strain in the nasal cavity than B. parapertussis Awbm infection did (Fig. 1, top right) . However, mice immunized with B. parapertussis Awbm harbored at least 8,000-fold more B. parapertussis bacteria in the lungs, 104,9 CFU, than B. parapemm/.s-immiiiiized mice (P < 0.01) (Fig. 1, bottom) (Fig. 2, white bars) . Although vaccina tion with B. parapertussis Awbm reduced B. parapertussis num bers in the LRT (Fig. 2, striped bars) , animals vaccinated with B. parapertussis Awbm had 160-, 16-, and 3-fold more bacteria in the lungs, trachea, and nasal cavity than B. parapertussisvaccinated animals (Fig. 2) (Fig. 4A, left) . B. parapertussis \wbm immunization sera had similar Ig titers when probed with the wild-type and O antigen mutant B. parapertussis strains (Fig. 4A, right) . Sera raised against B. parapertussis àwbm showed a 44% reduction in B. parapertuss/.s-speci lie antibody titers compared to those in sera raised against B. parapertussis (Fig. 4A, first (Fig. 4B) . Naïve sera appeared to minimally bind antigens from either lysate (Fig. 4B, lanes 1 and 2) . B. parapertussis-induced serum antibodies recognized a broad band or smear, band i, present in B. parapertussis lysate but not in B. parapertussis iswbm lysate (Fig. 4B, lanes 3 and 4) 14 postchallenge for bacterial enumera tion, since B. parapertussis poorly stimulates Toll-like receptor 4 (TLR4) and antibodies therefore have no effect until around day 14 after T cells have been generated (19, 55 ; D. N. Wolfe, unpublished data). Naive sera had no effect on bacterial loads throughout the respiratory tract on day 14 postchal lenge ( Fig. 6 ). As seen in previous studies (19, 56) (Fig. 1, 2 (19, 29, 30) . The data presented here are consistent with the findings of experimental studies using a mouse infection model, as well as those of clinical studies, in which B. pertussis immunity failed to induce protective immu nity to B. parapertussis (Fig. 7A) (9, 10, 14, 23, 27, 52, 56, 59 ). This work extends the findings of those previous studies to examine the role of the O antigen in the generation of B. parapertussis-specific immunity.
RESULTS

The
We found that although immunization with wild-type B. parapertussis induced protective immunity to both the wild type and the O-antigen-deficient B. parapertussis strains, prior infection or vaccination with the O-antigen-deficient strain conferred significantly less protection against the wild type in the lungs ( Fig. 1 and 2) . Immunization with B. parapertussis ¿Swbm induced splenic cytokine production similar to that in duced by wild-type vaccination (Fig. 3) , indicating that the decrease in protection conferred by the O-antigen-deficient strain was not due to inefficient T-cell cytokine production. Interestingly, B. parapertussis-induced antibodies recognized the O antigen as a dominant antigen (Fig. 4A and B, lanes 3  and 4) . Serum antibodies raised against the wild type, but not the O-antigen-deficient strain, mediated efficient opsonophagocytosis and reduced B. parapertussis colonization upon passive transfer (Fig. 5) (Fig. 1) . These antigens are present in the B. paraper tussis lysate (Fig. 4B), (Fig. 4 to 6 The O antigen seems to contribute to the generation of effective protective immunity against B. parapertussis in the lungs but not in the trachea or nasal cavity ( Fig. 1 and 2 Fig. 1 and 2 ). This pattern may be due to different clearance mechanisms in in fection-and vaccination-induced immunity to bordetellae (12) . Vaccination is efficient in controlling disease but may be less effective in preventing subclinical colonization, as observed with B. pertussis (28) . While the nasal cavity may be a reservoir of asymptomatic carriage of B. parapertussis, the protection in the lungs correlates with vaccine efficacy against severe disease and is thus the focus of this study (9) .
The incidence of whooping cough has increased over the past 20 years, despite the maintenance of excellent vaccine coverage in developed countries (5) . This trend may be due, at least in part, to vaccines' being ineffective against B. paraper tussis-induced disease (9, 16, 23) . Of note, the switch from whole-cell to acellular vaccines correlates with increased prev alence of B. parapertussis (23) . Moreover, whooping cough vaccinations have been proposed to shape the age-incidence patterns of the two causative agents. B. pertussis is more com mon in infants prior to vaccination and adolescents in whom vaccine-induced immunity has waned (6, 53) (20, 26, 55) , thereby removing the TLR4 agonist, lipid A, to which is attributed most of the proinflammatory stimulation (32) . Alternatively, other, as-yet-unidentified antigens of B. parapertussis may prove to be protective and could be added to acellular whoop ing cough vaccines. However, the poor protection conferred by the O-antigen-deficient strain and the ability of the O antigen to block the effects of antibodies recognizing other antigens (56, 59) 
